Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03288545
Title A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

transitional cell carcinoma

Therapies

Atezolizumab + Enfortumab vedotin-ejfv + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN


No variant requirements are available.